ArticleJournal for immunotherapy of cancer2021
Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).
Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 67 citations in OpenAlex.
- Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.MedScience · 2026Review
- SARS-CoV-2-specific T cells cross-react with tumor-associated antigens via molecular mimicry.Journal of translational medicine · 2026Article
- In silico design and evaluation of a candidate multiepitope Salmonella vaccine construct targeting broad-spectrum protection in poultry.BMC genomics · 2026Article
- Multi-strain dengue antigen design: from epitope prediction to monoclonal antibody binding and dynamics.Journal of molecular modeling · 2026Article
- Cross-reactive tissue-resident memory T lymphocytes-concepts, evidence, and open questions.Journal of translational medicine · 2026Review
- Enteroviral epitope mimicry enables NK cell-mediated targeting of ASPH in hepatocellular carcinoma.bioRxiv : the preprint server for biology · 2026Article
- In silico design of a multiepitope vaccine against antibiotic drug-resistant Acinetobacter baumannii.Scientific reports · 2026Article
- Design of a novel epitope-based tetravalent subunit vaccine against dengue virus: An immunoinformatic approach.PloS one · 2026Article
- Optimized Multi-Epitope Norovirus Vaccines Induce Robust Humoral and Cellular Responses in Mice.Vaccines · 2025Article
- Development and Immunogenicity Assessment of a Multi-Epitope Antigen Against Zika Virus: An In Silico and In Vivo Approach.Vaccines · 2025Article
- Article
- Development of a Broad-Spectrum Pan-Mpox Vaccine via Immunoinformatic Approaches.International journal of molecular sciences · 2025Article
- Mandatory preventive vaccines for infectious diseases expressing T-cell epitopes for cancer prevention.Infectious agents and cancer · 2025Article
- Gut microbiota in cancer initiation, development and therapy.Science China. Life sciences · 2025Review
- A tumor-binding antibody with cross-reactivity to viral antigens.Cancer immunology, immunotherapy : CII · 2025Article
- Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer.Journal for immunotherapy of cancer · 2025Article
- Tuberculosis vaccines and therapeutic drug: challenges and future directions.Molecular biomedicine · 2025Review
- Advancements and challenges in personalized neoantigen-based cancer vaccines.Oncology reviews · 2025Review
- Design of a multi-epitope recombinant BCG vaccine targeting Brucella OMP31, LptE and VirB2 in immunoinformatics approaches.PloS one · 2025Article
- Unveiling cross-reactivity: implications for immune response modulation in cancer.Briefings in bioinformatics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe host's immune system develops in equilibrium with both cellular self-antigens and non-self-antigens derived from microorganisms which enter the body during lifetime. In addition, during the years, a tumor may arise presenting to the immune system an additional pool of non-self-antigens, namely tumor antigens (tumor-associated antigens, TAAs; tumor-specific antigens, TSAs).
methodsIn the present study, we looked for homology between published TAAs and non-self-viral-derived epitopes. Bioinformatics analyses and ex vivo immunological validations have been performed.
resultsSurprisingly, several of such homologies have been found. Moreover, structural similarities between paired TAAs and viral peptides as well as comparable patterns of contact with HLA and T cell receptor (TCR) α and β chains have been observed. Therefore, the two classes of non-self-antigens (viral antigens and tumor antigens) may converge, eliciting cross-reacting CD8
conclusionsAn established antiviral T cell memory may turn out to be an anticancer T cell memory, able to control the growth of a cancer developed during the lifetime if the expressed TAA is similar to the viral epitope. This may ultimately represent a relevant selective advantage for patients with cancer and may lead to a novel preventive anticancer vaccine strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.